Cabio Biotech (Wuhan) (688089) Stock Overview
Engages in the research, development, production, and sale of functional ingredients and bio-based products in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
688089 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Cabio Biotech (Wuhan) Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.47 |
| 52 Week High | CN¥26.60 |
| 52 Week Low | CN¥6.91 |
| Beta | 0.41 |
| 1 Month Change | 12.78% |
| 3 Month Change | -26.73% |
| 1 Year Change | -67.70% |
| 3 Year Change | -56.41% |
| 5 Year Change | -78.13% |
| Change since IPO | -74.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688089 | CN Chemicals | CN Market | |
|---|---|---|---|
| 7D | -1.4% | 2.3% | 1.7% |
| 1Y | -67.7% | 17.2% | 0.9% |
Return vs Industry: 688089 underperformed the CN Chemicals industry which returned 17.2% over the past year.
Return vs Market: 688089 underperformed the CN Market which returned 0.9% over the past year.
Price Volatility
| 688089 volatility | |
|---|---|
| 688089 Average Weekly Movement | 7.9% |
| Chemicals Industry Average Movement | 7.6% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in CN Market | 11.8% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 688089 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688089's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 500 | Dewei Yi | www.cabio.cn |
Cabio Biotech (Wuhan) Co., Ltd. engages in the research, development, production, and sale of functional ingredients and bio-based products in China and internationally. The company offers polyunsaturated fatty acids, including arachidonic acid (ARA) and docosahexaenoic acid (DHA); terpenoids, such as beta (ß)-carotene and astaxanthin; and carbohydrates, such as N-acetylneuraminic acid and human milk oligosaccharides. Its products are used in human nutrition, including early life nutrition and dietary supplements; animal nutrition, such as economic animal and pet nutrition; personal care and cosmetics; and synthetic biology applications.
Cabio Biotech (Wuhan) Co., Ltd. Fundamentals Summary
| 688089 fundamental statistics | |
|---|---|
| Market cap | CN¥1.42b |
| Earnings (TTM) | -CN¥64.80m |
| Revenue (TTM) | CN¥313.99m |
Is 688089 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688089 income statement (TTM) | |
|---|---|
| Revenue | CN¥313.99m |
| Cost of Revenue | CN¥253.75m |
| Gross Profit | CN¥60.25m |
| Other Expenses | CN¥125.05m |
| Earnings | -CN¥64.80m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 19.19% |
| Net Profit Margin | -20.64% |
| Debt/Equity Ratio | 11.6% |
How did 688089 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 06:58 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cabio Biotech (Wuhan) Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li Wu | Tianfeng Securities Brokerage Co., Ltd |
| Jinsong Fan | Zhongtai Securities Co. Ltd. |